Famitinib (SHR-1020)
Gastrointestinal Stromal Tumor (GIST)
Key Facts
Indication
Gastrointestinal Stromal Tumor (GIST)
Phase
Approved
Status
Marketed in China
Company
About Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine's mission is to advance healthcare through high-quality, innovative medicines, solidifying its position as China's largest and most valuable pharmaceutical company. Its key achievements include building a massive pipeline of 719 drug candidates, successfully launching multiple blockbuster oncology drugs in China, and establishing international R&D footprints. The company's strategy centers on aggressive investment in proprietary R&D, a dual-track approach of 'innovation + internationalization,' and dominating key therapeutic areas like oncology while expanding into metabolic, autoimmune, and neurological diseases.
View full company profileTherapeutic Areas
Other Gastrointestinal Stromal Tumor (GIST) Drugs
| Drug | Company | Phase |
|---|---|---|
| SAR003 | Sartar Therapeutics | Pre-clinical |
| Pasritamig | Zymeworks | Phase 2/3 |